Brookfield to invest $600 million in ACME’s green molecules

Brookfield has agreed to invest $600 million in

Cleantech Ventures through a structured equity deal. The capital will fund four green ammonia and methanol projects across India and Oman. This matters because ACME is positioning itself as a key supplier of cost‑competitive green molecules, with projects backed by offtake agreements from SECI, Yara International, IHI Corporation, Mitsubishi Gas Chemicals and major Indian fertilizer companies. The first phase of its Oman project is already funded and due by March 2027, while Odisha units are expected by 2028 and a JV project by 2029. The headline number highlights Brookfield’s entry into the sector, but the deeper story is about long‑term cash flow visibility. ACME’s strategy relies on binding export contracts and partnerships to secure demand. That reduces project risk but does not eliminate execution challenges. Valuation for the deal will only be fixed in late 2026, leaving uncertainty on how much equity Brookfield will ultimately own. ACME has stated it will retain majority control. From an investment view, the deal validates ACME’s pipeline and signals growing institutional interest in India’s green molecules market, projected to grow at a 10.8% CAGR to $270 billion by the early 2030s. However, timelines stretch into 2027–2029, meaning near‑term earnings visibility is limited. Investors should watch for commissioning milestones, clarity on project economics, and whether ACME can deliver cost‑competitive output at scale. The call: Brookfield’s backing strengthens ACME’s credibility, but the investment case hinges on execution and long‑term demand materializing. For now, this is a strategic validation rather than an immediate earnings story. Disclosure: This article is for informational purposes only and does not constitute investment advice.